|
|
||||||||
Eur J Cardiothorac Surg 2005;27:329-333
© 2005 Elsevier Science NL
Section of Thoracic Surgery, Salamanca University Hospital, 37007 Salamanca, Paseo de San Vicente 58, Spain
Received 20 August 2004; received in revised form 3 November 2004; accepted 8 November 2004.
* Corresponding author. Tel./fax: +34 923 291 383. (E-mail: gvs{at}usal.es).
| Abstract |
|---|
|
|
|---|
. For the whole series, mean hospital
stay was 5 days (10 days for patients with PAL). PAL cases had more
postoperative pulmonary morbidity (risk-ratio: 2.78). Variables showing
independent influence on stay were: diagnosis of non-malignant disease
(P=0.001); FEV1ppo (P=0.032) and
cardio-respiratory morbidity (P<0.001). Calculated total excess
stay for PAL patients was 62 days. A total expense of 39,437.39
(38,724.96
hospital and 712.43
pharmacy charges) were estimated
to result from postoperative air-leak. Conclusions: PAL patients are
prone to developing major postoperative morbidity. PAL calculated costs are
over 13000
per year. This data is useful for designing technical cost-effective strategies to avoid post-lobectomy PAL.
Key Words: Lung resection Adverse outcomes Postoperative air-leak Hospital costs
| 1. Introduction |
|---|
|
|
|---|
The main objective of this investigation is to quantify economic costs directly attributable to PAL in a series of pulmonary lobectomies. Other specific objectives are: (1) to measure prevalence of PAL; (2) to compare the prevalence of pleural empyema and pneumonia in cases with or without postoperative PAL; and (3) to evaluate the influence of PAL and other clinical variables on LOS.
| 2. Methods |
|---|
|
|
|---|
2.2. Patient population
A series of patients undergoing lobectomy in our Centre from January 2001 to December 2003 has been analysed. Clinical criteria for operation and hospital discharge have been published elsewhere [4]. In all cases, predicted postoperative FEV1 (ppoFEV1) was preoperatively calculated [5]. Most operations were performed through a muscle-sparing limited video-assisted thoracotomy. Adhesives, pleural tents or suture reinforcements were not routinely indicated. In presence of severe emphysema, synthetic-absorbable sealant [6] was discretionally available. One single water seal chest drain was left after resection under no wall suction. Postoperative pain was controlled by thoracic epidural analgesia and intensive physical therapy was begun the morning after surgery. Medical therapy was also pre and postoperatively standardised for chronic obstructive pulmonary disease, deep vein thrombosis prophylaxis, nosocomial pneumonia and postoperative atrial fibrillation.
2.3. Variables analysed
From the beginning of the Unit activities, all clinical variables were codified and prospectively recorded in a computerized database. A routine to control clinical information quality was instituted and all records reviewed by the same person before sending definitive data to the hospital central archive. Variables and outcomes were defined as follows:
1. Outcomes: PAL was defined as persistence of air-leak through the chest drain for 5 days or more.
LOS: Difference between hospital admission and discharge dates.
Pulmonary complication: pneumonia, pulmonary atelectasis and pleural empyema were considered. Nosocomial pneumonia was diagnosed by clinical criteria following Centers for Diseases Control [7] and The American Thoracic Society [8] recommendations.
Pulmonary lobar collapse was diagnosed by chest X-ray in all cases and treated by physical therapy. An aspirative bronchoscopy was indicated in cases unresponsive to physical measures.
Pleural empyema was diagnosed in the presence of purulent exudate through the chest drain and clinical signs of infection. Biochemical parameters were not considered for diagnosis.
2. Independent variables studied were: Age of the patient, diagnosis (malignant vs. inflammatory disease), body-mass index (BMI), ppoFEV1 valueas a percentage of the normal, preoperative co-morbidity index [9] and major postoperative cardio-respiratory morbidity (binary variable; any of the following postoperative events were considered: pulmonary atelectasis or pneumonia, need of mechanical ventilation at any time after extubation in the operating room, pulmonary thromboembolism, arrhythmia, myocardial ischemia or infarct, clinical cardiac insufficiency, pleural empyema and bronchial fistula).
3. Economic data: Costs were obtained for each case from the hospital accounting department and from the hospital pharmacy department. Daily costs included hospital and pharmacy charges but operating room charges were considered homogeneous in all cases and excluded from the study.
2.4. Statistics
Descriptive statistics have been performed for independent variables and outcomes. Rates of nosocomial infection in PAL and non-PAL cases were arranged in 2x2 table and odds ratio (and its 95% confidence intervals) calculated. Probability of discharge was calculated by Cox regression analysis including the following variables in the model: age, diagnosis, BMI, ppoFEV1, co-morbidity index and postoperative cardio-respiratory morbidity. Log-rank test was used to evaluate differences in discharge probabilities between populations with and without PAL. Using clinical characteristics of each patient (age, diagnosis, BMI, ppoFEV1, co-morbidity index and postoperative cardio-respiratory morbidity) expected individual LOS was estimated by Cox-regression analysis. This value was plotted against individual true LOS. Difference between estimated and true LOS was found for each patient and the total LOS excess for PAL cases calculated. Cases with missing data were not entered in the model. Mean hospital charges were multiplied by the total days of excess stay. Mean daily pharmacy costs were obtained separately for patients with and without postoperative major cardio-respiratory morbidity and values used to calculate estimated excess of pharmacy expenses.
| 3. Results |
|---|
|
|
|---|
|
|
|
|
|
|
) and
pharmacy charges (16.80
in cases suffering major postoperative
morbidity and 8.20
in cases without postoperative adverse events) are
multiplied by excess stay for each case, resulting in 38,724.96
related to hospital and 712.43
related to pharmacy charges. An
estimated total expense of 39,437.39
resulted from postoperative air-leak. | 4. Discussion |
|---|
|
|
|---|
There is no standard definition of PAL in the literature. In several reports, PAL is considered after 7 [11,12] or 10 days [13]. In our report, we have defined PAL as air-leak for 5 or more days and we consider this to be more in concordance with the median hospital stay reported in our series (5 days).
According to our definition of PAL, it is reasonable to expect prolonged LOS in such complicated cases, as previously reported by others [3,11]. To avoid prolonged LOS and associated expenses, Cerfolio et al. [14] discharged home their PAL cases under Heimlich valve drainages. We consider this to be an excellent and secure practice for patients living in the hospital surroundings (which is not the case in most of our patients) but it is probably not free of expenses since, costs are shifted to primary or ambulatory care services.
In this report, we have implemented a mathematical LOS estimation from several clinical variables. Such a calculation is at its most accurate when dealing with large databases, which is not the case here and therefore our results should be interpreted with caution due to their variability. We have estimated a total of 62 excess days of hospital stay in PAL cases. Then, using direct medical (excluding operating room and drugs) and non-medical daily hospital costs we have calculated the total hospital expense attributable to PAL. We have supposed operating room costs homogeneous for all the series although in severe emphysema cases more suture machines and some sealants were probably used. Pharmacy charges have been independently considered since their value depends on the presence or absence of medical postoperative complications.
It is debatable whether all the excess stays were attributable to PAL, since, some of the patients also suffered cardio-respiratory post-operative morbidity. We have tried to demonstrate that PAL increases the risk of other postoperative morbidity. As we have shown, PAL patients have more than twice the probability of postoperative pulmonary complications than non-PAL cases. This is a clinically relevant finding although not statistically significant, probably due to the number of cases in the series.
As we have mentioned, three PAL patients were readmitted due to pneumothorax or infection that could have been related to PAL. We have not considered readmission expenses due to lack of evidence on the causes of the problem.
To avoid PAL, several surgical techniques have been published. Pleural tent seems to be an effective non-expensive practice in upper lobectomy cases [15,16]. Buttressed lung suture decreases hospital stay, according to Venuta et al. [17], but its results have not been reproduced by Miller et al. [18]. Using suture line sealants reduce air leak both in experimental [19,20] and clinical [6,21] settings and, despite reports that there is no scientific evidence supporting routine use of sealants [2], a prospective-randomised multi-centric study has been recently published [22] concluding that sealant use was associated with decreased LOS.
To the best of our knowledge, there are no published cost-effectiveness analyses of surgical strategies to avoid PAL. Economic evaluation of surgical practices depend on the quality of the underlying medical evidence [23]; cost-effectiveness analysis on PAL strategies then require well designed controlled clinical trials including a large enough number of cases to decrease the mathematical variability mentioned above. Such studies are difficult to conduct [24], especially in managed-care health systems [25].
To conclude PAL is a cause of prolonged LOS, accounting for more that 13,000
a year in our centre; PAL patients are prone to developing major postoperative morbidity.
| Appendix A. Conference discussion |
|---|
|
|
|---|
Dr Varela: To both questions, I'm afraid not. I can gather this information for the whole database, but it is not available at this moment. In our hospital, around 60% of operated cases for lung cancer have COPD, but I can't inform you at this time of the grade of emphysema.
Mr R. Berrisford (Exeter, UK): What is your policy on discharging patients with indwelling chest drains and flutter valves, because that would impact on your length of stay.
Dr Varela: I think this is a very important question. I think McKenna and maybe Cerfolio have published in the United States that they discharge patients having prolonged air leak with Heimlich valves. Unfortunately we are not in the situation to discharge most of our patients with such a valve because they live in rural areas away from the hospital, more than 100km or so. In such cases, maybe 90% of air leak patients have to stay in the hospital until they are reoperated in some cases or usually the air leak stops. To answer your question, only around 56% of air leak patients can be discharged with a Heimlich valve.
Dr S. Mattioli (Bologna, Italy): What is your policy in treating patients having prolonged air leaks?
Dr Varela: Do you mean what is our policy?
Dr Mattioli: Yes, do you switch the chest suction off?
Dr Varela: We almost never use suction in our cases since maybe 5 or 6 years ago. So the patient stays in the hospital, is treated by respiratory therapists, and the chest tube is connected to any kind of chest drainage unit, or even in some cases to a Heimlich valve.
| Footnotes |
|---|
Presented at the joint 18th Annual Meeting of the European Association for Cardio-thoracic Surgery and the 12th Annual Meeting of the European Society of Thoracic Surgeons, Leipzig, Germany, September 1215, 2004. | References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Brunelli, M. Salati, M. Refai, F. Xiume, G. Rocco, and A. Sabbatini Risk-adjusted econometric model to estimate postoperative costs: An additional instrument for monitoring performance after major lung resection J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 624 - 629. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Andreetti, F. Venuta, M. Anile, T. De Giacomo, D. Diso, M. Di Stasio, E. A. Rendina, and G. F. Coloni Pleurodesis with an autologous blood patch to prevent persistent air leaks after lobectomy J. Thorac. Cardiovasc. Surg., March 1, 2007; 133(3): 759 - 762. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gomez-Caro, M. J. R. Calvo, J. T. Lanzas, R. Chau, P. Cascales, and P. Parrilla The approach of fused fissures with fissureless technique decreases the incidence of persistent air leak after lobectomy Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 203 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Brunelli, F. Xiume, M. Al Refai, M. Salati, R. Marasco, and A. Sabbatini Air leaks after lobectomy increase the risk of empyema but not of cardiopulmonary complications: a case-matched analysis. Chest, October 1, 2006; 130(4): 1150 - 1156. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Tansley, F. Al-Mulhim, E. Lim, G. Ladas, and P. Goldstraw A prospective, randomized, controlled trial of the effectiveness of BioGlue in treating alveolar air leaks J. Thorac. Cardiovasc. Surg., July 1, 2006; 132(1): 105 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Anegg, J. Lindenmann, V. Matzi, D. Mujkic, A. Maier, L. Fritz, and F. M. Smolle-Juttner AIRFIX((R)): the first digital postoperative chest tube airflowmetry-a novel method to quantify air leakage after lung resection. Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 867 - 872. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Thomas, G. Massard, H. Porte, C. Doddoli, X. Ducrocq, and M. Conti A new bioabsorbable sleeve for lung staple-line reinforcement (FOREsealtrade mark): report of a three-center phase II clinical trial. Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 880 - 885. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Varela, E. Ballesteros, M. F. Jimenez, N. Novoa, and J. L. Aranda Cost-effectiveness analysis of prophylactic respiratory physiotherapy in pulmonary lobectomy Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 216 - 220. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |